James N. Gerson, MD

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

James N. Gerson, MD, discusses recent updates in relapsed/refractory mantle cell lymphoma.

James N. Gerson, MD, discusses the emergence of targeted therapy in chronic lymphocytic leukemia.

James N. Gerson, MD, assistant professor of clinical medicine, Perelman School of Medicine, University of Pennsylvania, discusses strategies aimed at alleviating toxicity in older patients with mantle cell lymphoma (MCL).

James N. Gerson, MD, discusses the watch-and-wait approach for patients with mantle cell lymphoma.

James N. Gerson, MD, discusses the phase III CLL14 trial evaluating the combination of venetoclax and obinutuzumab versus chlorambucil and obinutuzumab as frontline therapy in chronic lymphocytic leukemia.